scholarly journals Soluble interleukin-2 receptor as a predictive and prognostic marker for patients with familial breast cancer

2021 ◽  
Vol 104 (3) ◽  
pp. 003685042110395
Author(s):  
Kenji Gonda ◽  
Shoichiro Horita ◽  
Yuko Maejima ◽  
Seiichi Takenoshita ◽  
Kenju Shimomura
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Regulatory T Cell ◽  
Familial Breast Cancer ◽  
Interleukin 2 ◽  
Suppressor Cell ◽  
Breast Cancer Patients ◽  
Interleukin 2 Receptor ◽  
Myeloid Derived Suppressor Cell ◽  
Soluble Interleukin 2 Receptor

The incidence of breast cancer increases annually, and it has become common within families of breast cancer patients. Interleukin-2 activates cytotoxic T lymphocytes, which are important for cancer immunity. To identify markers of increased familial breast cancer risk, soluble interleukin-2 receptor levels and immunologic factors were investigated in familial breast cancer and non-familial breast cancer patients. Of 106 untreated breast cancer patients in this study, 24 had familial breast cancer and 82 had non-familial breast cancer. The patients’ soluble interleukin-2 receptor, interleukin-10, vascular endothelial growth factor, interleukin-17, regulatory T cell, myeloid-derived suppressor cell, white blood cell, and C-reactive protein levels, and their neutrophil-to-lymphocyte ratios were measured, and their prognoses were compared according to the soluble interleukin-2 receptor levels. Additionally, postoperative tissues from the patients with high soluble interleukin-2 receptor levels were stained with programmed cell death ligand 1 and cluster of differentiation 8. The soluble interleukin-2 receptor level in the familial breast cancer patients was significantly higher, and it showed significantly stronger correlations with the neutrophil-to-lymphocyte ratio and the interleukin-10, vascular endothelial growth factor, interleukin-17, regulatory T cell, myeloid-derived suppressor cell, white blood cell, and C-reactive protein levels, than in the non-familial breast cancer patients. The regulatory T cell and myeloid-derived suppressor cell levels were significantly higher in the patients with high soluble interleukin-2 receptor levels, and the overall survival and disease-free-survival rates were significantly worse for the familial breast cancer patients than for the non-familial breast cancer patients. Triple-negative breast cancer tissues from the familial breast cancer patients with high soluble interleukin-2 receptor levels stained well for programmed cell death ligand 1 and cluster of differentiation 8. Soluble interleukin-2 receptor levels can be used to predict the prognosis of familial breast cancer patients. Prospectively identifying patients who are less likely to have non-familial breast cancer is vital for improving their overall survival.

scholarly journals Prevalence of RECQL germline variants in Pakistani early-onset and familial breast cancer patients

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Muhammad Usman Rashid ◽  
Noor Muhammad ◽  
Faiz Ali Khan ◽  
Umara Shehzad ◽  
Humaira Naeemi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Onset ◽  
Familial Breast Cancer ◽  
High Performance ◽  
Breast Cancer Patients ◽  
Germline Variants ◽  
Variants Of Unknown Significance ◽  
Breast Cancer Predisposition ◽  
Novel Variants

Abstract Background The RecQ Like Helicase (RECQL) gene has previously been shown to predispose to breast cancer mainly in European populations, in particular to estrogen receptor (ER) and/or progesterone receptor (PR) positive tumor. Here, we investigated the contribution of pathogenic RECQL germline variants to hereditary breast cancer in early-onset and familial breast cancer patients from Pakistan. Methods Comprehensive RECQL variant analysis was performed in 302 BRCA1 and BRCA2 negative patients with ER and/or PR positive breast tumors using denaturing high-performance liquid chromatography followed by DNA sequencing. Novel variants were classified using Sherloc guidelines. Results One novel pathogenic protein-truncating variant (p.W75*) was identified in a 37-year-old familial breast cancer patient. The pathogenic variant frequencies were 0.3% (1/302) in early-onset and familial breast cancer patients and 0.8% (1/133) in familial patients. Further, three novel variants of unknown significance, p.I141F, p.S182S, and p.C475C, were identified in familial breast cancer patients at the age of 47, 68, and 47 respectively. All variants were absent in 250 controls. Conclusions Our data suggest that the RECQL gene plays a negligible role in breast cancer predisposition in Pakistan.

The expression of aphidicolin-induced fragile sites in familial breast cancer patients

1993 ◽  
Vol 67 (2) ◽  
pp. 108-112 ◽  
Author(s):  
Erika L.D. Mitchell ◽  
Brian Woodhouse ◽  
Jillian M. Birch ◽  
Mauro F. Santibanez-Koref
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Familial Breast Cancer ◽  
Fragile Sites ◽  
Breast Cancer Patients

Interleukin-2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients

Cancer ◽  
1988 ◽  
Vol 61 (4) ◽  
pp. 629-634 ◽  
Author(s):  
Felix Bonilla ◽  
Melchor Alvarez-mon ◽  
Francisco Merino ◽  
Antonio De La Hera ◽  
José Enrique Alés ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cytotoxic Activity ◽  
Cancer Patients ◽  
Interleukin 2 ◽  
Breast Cancer Patients ◽  
Axillary Nodes

Immunomodulatory Activities of Yunzhi and Danshen in Post-treatment Breast Cancer Patients

2005 ◽  
Vol 33 (03) ◽  
pp. 381-395 ◽  
Author(s):  
Chun-Kwok Wong ◽  
Yi-Xi Bao ◽  
Eliza Lai-Yi Wong ◽  
Ping-Chung Leung ◽  
Kwok Pui Fung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Weight ◽  
Cancer Patients ◽  
Salvia Miltiorrhiza ◽  
Interleukin 2 ◽  
Post Treatment ◽  
Enzyme Linked Immunosorbent Assay ◽  
Breast Cancer Patients ◽  
T Helper ◽  
The Absolute

Breast cancer is the most common cancer among women worldwide. Discomfort and fatigue are usually arisen from anticancer therapy such as surgery, radiotherapy, chemotherapy, hormonal therapy, or combination therapy, because of the suppressed immunological functions. Yunzhi (Coriolus versicolor) can modulate various immunological functions in vitro, in vivo, and in human clinical trials. Danshen (Salvia miltiorrhiza) has been shown to benefit the circulatory system by its vasodilating and anti-dementia activity. The purpose of this clinical trial was to evaluate the immunomodulatory effects of Yunzhi-Danshen capsules in post-treatment breast cancer patients. Eighty-two patients with breast cancer were recruited to take Yunzhi [50 mg/kg body weight, 100% polysaccharopeptide (PSP)] and Danshen (20 mg/kg body weight) capsules every day for a total of 6 months. EDTA blood samples were collected every 2 months for the investigation of immunological functions. Flow cytometry was used to assess the percentages and absolute counts of human lymphocyte subsets in whole blood. Plasma level of soluble interleukin-2 receptor (sIL-2R) was measured by enzyme-linked immunosorbent assay (ELISA). Results showed that the absolute counts of T-helper lymphocytes (CD4+), the ratio of T-helper (CD4+)/T suppressor and cytotoxic lymphocytes (CD8+), and the percentage and the absolute counts of B-lymphocytes were significantly elevated in patients with breast cancer after taking Yunzhi-Danshen capsules, while plasma sIL-2R concentration was significantly decreased (all p < 0.05). Therefore, the regular oral consumption of Yunzhi-Danshen capsules could be beneficial for promoting immunological function in post-treatment of breast cancer patients.

scholarly journals Sister chromatid exchange: A possible approach to characterize familial breast cancer patients

2014 ◽  
Vol 33 (2) ◽  
pp. 930-934 ◽  
Author(s):  
IVANA DE PASCALIS ◽  
BRUNELLA PILATO ◽  
ANNALISA MAZZOTTA ◽  
TERESA STEFANIA DELL’ENDICE ◽  
VINCENZA RUBINI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Sister Chromatid ◽  
Sister Chromatid Exchange ◽  
Familial Breast Cancer ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document